Basit öğe kaydını göster

dc.contributor.authorAyer, Mesut
dc.contributor.authorSuer, Ilknur
dc.contributor.authorCefle, Kivanc
dc.contributor.authorPalanduz, Sukru
dc.contributor.authorOzturk, Sukru
dc.contributor.authorNalcaci, Meliha
dc.contributor.authorAbacı, Neslihan
dc.contributor.authorSariman, Melda
dc.contributor.authorSalman Yaylaz, Burcu
dc.contributor.authorYabaci Tak, Aysegul
dc.contributor.authorSirma Ekmekci, Sema
dc.date.accessioned2023-10-10T12:10:20Z
dc.date.available2023-10-10T12:10:20Z
dc.date.issued2023
dc.identifier.citationSariman M., Salman Yaylaz B., Yabaci Tak A., Ayer M., Sirma Ekmekci S., Suer I., Cefle K., Palanduz S., Ozturk S., Nalcaci M., et al., "Evaluation of TMED9, DNAJC1, LMAN2, COPE and KDELR1 Biomarkers in Patients with Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma", UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, cilt.33, sa.2, ss.92-102, 2023
dc.identifier.issn1306-133X
dc.identifier.othervv_1032021
dc.identifier.otherav_1b715ae4-2d9d-4283-b05b-1918bc481c47
dc.identifier.urihttp://hdl.handle.net/20.500.12627/189940
dc.identifier.urihttps://doi.org/10.4999/uhod.236990
dc.description.abstractPlasma cell dyscrasias (PCD) are a heterogeneous group of hematological diseases. The TMED9, KDELR1, DNAJC1, COPE, and LMAN2 genes identified from our transcriptome data are highly importance and specific. We determined the protein-protein interac-tions of these genes in STRING v11.5 higher than expected (PPI enrichment p value 1.71e-06). We evaluated the prognostic bio-marker status of these genes in PCD by quantitative method (qRT-PCR) of 38 Multiple Myeloma (MM), 23 Monoclonal Gammopathy of Undetermined Significance (MGUS) and 16 control groups. We found significant gene expression levels increase among these three study groups of these genes (p< 0.001). As a single marker, DNAJC1 exhibited the best ability for discriminating MM from MGUS (AUC= 83%) and MM from control (AUC= 88.7%). In addition to this, the combination of five genes exhibited the highest efficacy of discriminating MM from the control (AUC= 90.90%). The combination of KDELR1, COPE, TMED9 and DNAJC1 exhibited the best ability to discriminate MM group from MGUS group (AUC= 86.80%). In conclusion, we showed that DNAJC1 alone, as well as the combination of other selected genes, can be valuable targets in the pathogenesis of myeloma. These new biomarkers have been evaluated for the first time in PCD and we think they will contribute to the discovery of potential anti-myeloma therapeutic targets in the future.
dc.language.isoeng
dc.subjectTıp (çeşitli)
dc.subjectKlinik Tıp (MED)
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKlinik Tıp
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectTIP, GENEL & DAHİLİ
dc.subjectGENETİK VE KALITIM
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectTıbbi Genetik
dc.subjectSağlık Bilimleri
dc.subjectGenel Sağlık Meslekleri
dc.subjectPatofizyoloji
dc.subjectTemel Bilgi ve Beceriler
dc.subjectDeğerlendirme ve Teşhis
dc.subjectDahiliye
dc.subjectGenetik (klinik)
dc.subjectAile Sağlığı
dc.subjectGenel Tıp
dc.subjectGenetik
dc.subjectYaşam Bilimleri
dc.titleEvaluation of TMED9, DNAJC1, LMAN2, COPE and KDELR1 Biomarkers in Patients with Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
dc.typeMakale
dc.relation.journalUHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume33
dc.identifier.issue2
dc.identifier.startpage92
dc.identifier.endpage102
dc.contributor.firstauthorID4410297


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster